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Abstract
Despite the identification of an increasing number of candidate genes involved in spermatogenesis, the armamentarium of 
diagnostic genetic tests in male infertility remains extremely limited. A number of new causative mutations have been reported 
for hypogonadotrophic hypogonadism but still the genetic diagnosis in this pathological condition is made only in about 20% 
of cases. The sole molecular genetic test that is routinely proposed in severe spermatogenic disturbances is screening for Yq 
microdeletion. The search for causative mutations in the Y chromosome, and in autosomal and X-linked genes, has mostly been 
unsuccessful. The paucity of gene mutations raises questions about the appropriateness of the currently used screening approaches. 
Among the proposed genetic risk factors, gr/gr deletion of the Y chromosome seems to be the most promising polymorphism. 
Other polymorphisms are awaiting further confirmation, whereas for some (POLG, DAZL, USP26, FSHR) a lack of association 
with abnormal spermatogenesis has now been ascertained. It is likely that some polymorphisms lead to testicular dysfunction only 
when in association with a specific genetic background or with environmental factors. Future large-scale studies with stringent 
study design may provide a more efficient way to identify clinically relevant genetic factors of male infertility.
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Spermatogenesis can be altered by different factors acting 
either at the pretesticular or directly at the testicular level. 
Despite a significant improvement in the diagnostic work-up 
of infertile men, in about 50% of cases the cause of abnormal 
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spermatogenesis remains unknown and is called idiopathic 
infertility (Forti and Krausz, 1998). Considering the high 
number of predicted genes involved in male gametogenesis, it 
is highly likely that mutations or polymorphisms in candidate 
genes involved in spermatogenesis are responsible for the 
majority of idiopathic forms of spermatogenic disturbances.
To date, candidate spermatogenesis genes have been identified 
mainly through model organisms, expression studies, linkage 
analysis and cytogenetic findings (for review, see Matzuk and 
Lamb, 2002). Recently, the approaches of transcriptomics and 
proteomics have been applied in this field and open a new 
perspective in understanding male infertility (Ostermeier et al., 
2002; Martinez-Heredia et al., 2006; Platts et al., 2007).
This review focuses on data available in the literature on gene 
mutations/polymorphisms with ascertained or potential clinical 
relevance in human spermatogenesis.
Genes involved in the endocrine 
regulation of spermatogenesis
Spermatogenesis and steroidogenesis in the testis is regulated 
through the hypothalamic–pituitary–testicular axis and involves 
a number of hormones such as gonadotrophin-releasing hormone 
(GnRH), FSH, LH, testosterone, oestrogens and inhibin B.
Congenital gonadotrophin deficiency and 
spermatogenic failure
Mutations in genes responsible for the migration of GnRH 
neurons, such as anosmin-1 (KAL1), fibroblast growth factor 
receptor 1 (FGFR1), G-protein-coupled prokineticin receptor-
2 (PROKR2), prokineticin-2 (PROK2) or mutations in the 
gonadotrophin-releasing hormone receptor (GnRH-R) gene 
or G-protein-coupled receptor 54 (GPR54) cause congenital 
hypogonadotrophic hypogonadism (for review, see Trarbach 
et al., 2007). Depending on the type of gene involved, these 
genetic anomalies can be associated with anosmia (Kallmann 
syndrome) or normosmia. Although sporadic cases are more 
frequent, families with Kallmann syndrome have been reported 
with X-linked, autosomal dominant or recessive modes of 
inheritance. The penetrance of the same mutation may vary 
in different family members, leading to a wide phenotype 
spectrum including the presence/absence of non-reproductive 
and non-olfactory disorders. Gonadotrophin deficiency can also 
be due to mutations of the beta subunits of LH and FSH. To 
date, only three distinct FSH and two LH beta subunit gene 
mutations have been described (Huhtaniemi, 2006). Given that 
the screening for mutations in all the above-described genes 
provides the identification of mutations only in about 20% of 
cases, additional genetic causes are expected to be discovered 
in the future. The diagnosis of congenital hypogonadotrophic 
hypogonadism is normally made before adulthood since it is 
associated with delayed puberty. In adulthood, spermatogenesis 
can be relatively easily induced by hormonal treatment; 
congenital hypogonadotrophic hypogonadism therefore 
represents a peculiar group of treatable forms of spermatogenic 
disturbance of genetic origin.
Steroid receptor gene mutations
The crucial role of androgens and oestrogens in the endocrine 
regulation of spermatogenesis is well known; therefore, genes 
of their receptors are a logical target for mutational analysis in 
infertile males.
The androgen receptor (AR) is a ligand-activated transcription 
factor that is encoded by the AR gene located on the long arm of 
the X chromosome (Xq11–q12). A large number of mutations in 
the AR gene have been identified worldwide and are available at 
the Androgen Receptor Gene Mutations Database (Gottlieb et 
al., 2004). Functional assays have demonstrated that a significant 
number of these mutations result in lower ligand binding or 
transactivation potential of the mutant receptor molecule. 
Mutations in the AR gene result in mild-to-complete androgen 
insensitivity. The phenotypic features of complete androgen 
insensitivity syndrome are female external genitalia and absence 
of pubic hair. In partial androgen insensitivity syndrome, several 
different phenotypes are evident, ranging from predominantly 
female phenotype (female external genitalia, pubic hair with or 
without clitoromegaly, and partially to completely fused labia) 
through ambiguous genitalia to predominantly male phenotype 
with micropenis, perineal hypospadias and cryptorchidism 
(Quigley et al., 1995). The later phenotype is also termed as 
Reifenstein syndrome (Quigley et al., 1995). Patients with mild 
androgen insensitivity syndrome have male infertility as their 
primary or even sole symptom.
Only a few mutations have been reported in male infertility 
(Gottlieb et al., 2004; Ferlin et al., 2006) and most of them 
have resulted in the reduction of transactivation potential 
of the mutant protein. In a recent screening of 1517 azoo-
oligozoospermic individuals, 26 patients carrying AR mutations 
(20 different mutations) (1.7%) were found, and none in the 
control group (Ferlin et al., 2006; Rajender et al., 2007). 
There has been no correlation between the type of mutation 
and the subtype of infertility (azoospermia, oligozoospermia 
or oligoteratozoospermia). Moreover, the previously proposed 
high androgen sensitivity index seems not to be able to predict 
an accurate selection for AR mutation screening. Apart from the 
difficulty in preselecting patients for the analysis, the need for 
routine testing in infertile subjects is further questioned by other 
reports in which none or very few mutations were detected in a 
large series of idiopathic infertile men (Singh et al., 2006; for 
review see Rajender et al., 2007).
The analysis of polymorphic regions in exon 1 of AR has been 
the subject of a large number of publications (Tut et al., 1997; 
Dowsing et al., 1999; von Eckardstein et al., 2001; Rajpert-
de Meyts et al., 2002; Foresta et al., 2005). The polymorphic 
(CAG)n codes for a polyglutamine whereas the (GGC)n repeat 
codes for a polyglycine stretch. It has been demonstrated for 
the (CAG)n repeats in in-vitro experiments that the length of the 
polyglutamine tract, while remaining within the polymorphic 
range, is inversely correlated with the transactivation activity of 
the receptor (Tut et al., 1997). Concerning the (GGC)n repeat, 
a recent report showed that AR with GGN repeat lengths other 
than the most common one of 23 have lower transactivating 
capacity (Lundin et al., 2007).
Despite promising in-vitro data, the initial observations of a 
significant association between relatively long CAG repeats and 505
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impaired sperm production (Dowsing et al., 1999) have not been 
confirmed by subsequent studies (for review see Asatiani et al., 
2003). Similarly, it is still under question whether the (GGC)n 
repeat has a pathogenic role in abnormal spermatogenesis (see 
Krausz and Giachini, 2007).
Discrepancies in the literature maybe the consequence of: (i) 
ethnic differences (the association seems to be more consistent 
in Asiatic populations); (ii) the heterogeneity of the control 
(unselected men, proven fertile men or normospermic men) 
and of the infertile (different inclusion criteria) groups; (iii) 
inadequate sample size (especially in the first positive studies).
In conclusion, mutation screening of neither the AR nor the 
CAG repeats can be proposed as a routine diagnostic test in 
patients with abnormal spermatogenesis. Mutations of AR are 
rare and many of the mutations described in infertile men still 
need to be characterized for their functional consequences. 
Concerning CAG repeat length, this polymorphism is an 
unlikely risk factor for male infertility if we consider large 
studies only. However, the role of CAG repeat length in 
modulating androgen action is more evident in patients 
affected by hypoandrogenism (for example subjects affected 
by Klinefelter syndrome) and its analysis could be useful for 
the definition of thresholds at which testosterone treatment 
should be initiated, and to personalize the dosage of substitutive 
testosterone therapy (Zitzmann et al., 2004).
Oestrogen receptor
Although human and animal models have shown an association 
between oestrogen insufficiency and abnormal spermatogenesis, 
little attention has been paid to the role of oestrogen receptor 
(ESR) gene mutations or polymorphisms in male infertility.
The physiological responses to oestrogens are known to be 
mediated by at least two functional isoforms of ESR, namely 
ESR1 and ESR2, encoded by two different genes in different 
chromosomes (6q25 and 14q23–24, respectively). Both 
receptors share the common structure of the steroid/thyroid 
hormone nuclear receptor, differing in the C-terminal ligand-
binding domain and in the N-terminal transactivation domain 
(O’Donnell et al., 2001). Besides these two isoforms a third 
membrane receptor has been reported in different cellular 
models including human spermatozoa (Luconi et al., 2002). 
This membrane receptor is probably involved in the stimulatory 
effect on sperm capacitation, acrosome reaction, and fertilizing 
ability of 17β-oestradiol and environmental oestrogens observed 
in mouse spermatozoa (Adeoya-Osiguwa et al., 2004).
To date only one patient with an inactivating mutation in the 
ESR1 gene (Smith et al., 1994), and four patients with aromatase 
(CYP19) deficiency have been reported (Morishima et al., 1995; 
Carani et al., 1997; Deladoey et al., 1999; Maffei et al., 2004). 
The phenotypes of these patients are rather heterogeneous, 
ranging from normal sperm concentration but reduced sperm 
viability in cases of the ESR1 mutation, to oligozoospermia 
and bilateral cryptorchidism in cases of aromatase deficiency 
(Carani et al., 1997; Maffei et al., 2004).
The human ESR1 gene encodes a protein of 595 amino acids 
with a molecular mass of about 66 kDa. Genetic screening 
of the ESR1 gene locus has revealed the existence of several 
polymorphic sites. The most widely studied are the PvuII 
(T397C) and XbaI restriction fragment length polymorphisms 
in intron I and the (TA)n variable number of tandem repeats 
within the promoter region of the gene (Gennari et al., 2005). 
Recently a possible relationship between ESR1 polymorphisms 
and male infertility has been reported in Greek and Japanese 
populations (Kukuvitis et al., 2002; Suzuki et al., 2002). 
However, due to the relatively small study populations in both 
studies, the interpretation of these data remains difficult.
The most promising polymorphism is the (TA)n variable number 
of tandem repeats within the promoter region. The distribution 
of the TA genotype is not different between controls and patients, 
therefore this polymorphism cannot be considered a risk factor 
for male infertility. However, it has a significant effect on sperm 
output in both normospermic and infertile men (Guarducci et al., 
2006). The number of TA repeats showed a significant inverse 
correlation with sperm count, and consequently men with a 
higher TA repeat number on both alleles have significantly lower 
sperm production. A plausible explanation would be that not 
only a deficit of oestrogens, but also an exaggerated oestrogen 
action related to this genetic variant (eventually combined with 
environmental factors), can be deleterious. Since the individual 
sensitivity to xenoestrogens may depend on the type of ESR1, 
the screening for this polymorphism may be useful in subjects 
with high exposure to xenoestrogens. Another interesting ESR1-
gene-related polymorphism is the specific haplotype AGATA, 
resulting from the allelic combination of five single nucleotide 
polymorphisms (SNP) situated in a 50 Kb haplotype block 
of ESR1. The AGATA haplotype in the Japanese population 
has been reported as risk factor for cryptorchidism (Yoshida 
et al., 2005), whereas in the Italian population the tag SNP of 
the AGATA haplotype (SNP12) has a significant protective 
effect (Galan et al., 2007). The discrepancy between the 
Italian and the Japanese study may be related to genuine ethnic 
differences and/or different environmental conditions. A role 
for ESR2 gene SNP in male infertility has also been proposed 
recently (Aschim et al., 2005; Galan et al., 2005). Given that 
for each type of variant and haplotype there are only sporadic 
studies, it is important to confirm their clinical significance in 
other independent study populations. It would be especially 
interesting to verify their effect on spermatogenic potential in 
relation to different grades of exposure to xenoestrogens.
Genes involved in common cell 
functions
Studies on genes involved in common cell functions that are 
relevant also for normal spermatogenesis are relatively few and 
are mainly single studies, with the exception of the mitochondrial 
DNA polymerase γ (POLG) and the methylenetetrahydrofolate 
reductase (MTHFR) genes. To date, only polymorphisms with 
little or no clinical relevance have been described. The POLG 
gene CAG polymorphism (with a major allele at 10 repeats) has 
been the subject of an extensive debate in the last few years. 
POLG is the sole polymerase for mitochondrial DNA (mtDNA) 
and impaired activity of this protein leads to mitochondrial 
dysfunction through accumulation of mtDNA mutations. Lack 
of functional POLG may therefore lead to several cellular 
dysfunctions including altered cell proliferation. Rovio et al. 
(2001) proposed an association between the absence of the 
common 10 CAG allele and male infertility in a relatively 506
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small group of infertile and fertile men. Subsequent studies in 
populations from Europe (Krausz et al., 2004; Aknin-Seifer 
et al., 2005; Brusco et al., 2006) and New Zealand (Harris et 
al., 2006) failed to confirm this first observation. Similarly, the 
proposed association with unexplained infertility (Jensen et al., 
2004) was also rejected after having ruled out interpretation bias 
(Krausz et al., 2004). It is therefore clear that the POLG CAG 
polymorphism has no clinical significance either for idiopathic 
or for ‘unexplained’ male infertility.
MTHFR is one of the key enzymes in folate metabolism and 
reduces 5,10-methylenetetrahydrofolate to its biologically active 
form 5-methyltetrahydrofolate. The C677T polymorphism of the 
MTHFR gene has been extensively analysed in infertile patients 
from different populations (Bezold et al., 2001; Ebisch et al., 
2003; Stuppia et al., 2003; Singh et al., 2005; Park et al., 2005). 
The C677T mutation decreases MTHFR activity and it leads 
to a decrease in folate levels and an increase in homocysteine 
levels in the blood. Altered folic acid metabolism influences 
DNA methylation, and subjects with homozygous mutation 
677TT have a lower level of genomic DNA methylation 
than controls (Stern et al., 2000). Since aberrant DNA and 
protein methylation is likely to affect spermatogenesis, the 
C677T represent a logical target for mutation screening in 
patients with impaired spermatogenesis; however, results 
are discordant. Studies from Indian, African and south-east 
Asian populations agree that MTHFR gene polymorphism 
is significantly associated with abnormal spermatogenesis, 
whereas European studies have obtained conflicting results. It 
is also not clear if only homozygous (TT) or also heterozygous 
(CT) MTHFR polymorphism are of clinical relevance. The 
most likely explanation is that the polymorphism is relevant 
only in specific environmental conditions, such as low dietary 
intake of folates. The pharmacogenomic correlate of the above-
mentioned association studies is that idiopathic infertile carriers 
of the 677TT genotype may potentially benefit from folic acid 
supplementation.
Genes involved in specific 
spermatogenic functions
Autosomal and X-linked genes
A number of spermatogenesis autosomal and X-linked 
candidate genes have been identified (mainly based on 
animal models) and they represent the most obvious targets 
for mutation analysis in men with spermatogenic failure. 
However, the search for candidate gene mutations has not led 
to the identification of confirmed novel causative mutations 
for impaired sperm production. The few available examples 
of ‘causative mutations’ are reported in Table 1, and they are 
mainly related to the endocrine control of spermatogenesis. 
In contrast, the number of genetic variants proposed as risk 
factors for male infertility are constantly increasing. However, 
in many cases only sporadic data are available and when more 
studies are published on the same polymorphism the results 
are often contradictory. Inadequate sample size, pathogenetic 
heterogeneity of infertility, inappropriate control subjects 
and ethnic/geographic differences (probably also related to 
environmental factors) may be responsible for discrepancies 
among case–control studies. Table 1 contains a comprehensive 
list of candidate genes that were screened for mutations in 
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Table 1. Summary of mutations with cause–effect relationship (causative) and polymorphisms proposed as risk factors for 
abnormal spermatogenesis. 
Mutation Gene  
	 Endocrine	regulation	of		 Specific	spermatogenic	 Common	cell	function 
 spermatogenesis function 
Causative AR, KAL-1, FGFR1, PROK2,  USP9Y, SYCP3 
 PROK2R, GnRH, GnRHR, GPR54,  
 FSH, LH, ESR1, CYP19 
Polymorphisms  
(single study) CYP19A1, NRIP1 GRTH, CREM-ACT, KIT-KITLG,  GSTM1, PHGPx, BRCA2, MS, 
  HANP1/H1T2, PUMILIO2,  MTRR, APOB, SDHA 
  BOULE
Polymorphisms  AR, FSHR, ESR1, ESR2 DAZL, PRM1–PRM2,  POLG, MTHFR 
(more than one   TNP1–TNP2, USP26 
study) 
For gene polymorphisms indicated in bold, a role as ‘risk factor’ has not been confirmed in Caucasian populations. Genes: ACT = activator of CREM in the testis; 
APOB = apolipoprotein B; AR = androgen receptor; BRCA = breast cancer; CREM = cAMP-responsive element modulator; CYP19A1 = CYP19 aromatase; DAZL = 
deleted azoospermia-like; ESR = oestrogen receptor; FGFR1 = fibroblast growth factor receptor 1; FSHR = FSH receptor; GnRH = gonadotrophin-releasing hormone; 
GnRHR = gonadotrophin-releasing hormone receptor; GPR54 = G-protein-coupled receptor 54; GRTH = gonadotrophin-regulated testicular helicase; GSTM1 = 
glutathione S-transferase M1; HANP1/H1T2 = histone H1-like, nuclear protein 1; KAL1 = Kallmann syndrome 1; KIT = v-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homologue; KITLG = KIT ligand; MS = methionine synthase; MTHFR = 5,10-methylenetetrahydrofolate reductase; GSTM1 = glutathione S-transferase 
M1; PHGPx = phospholipid hydroperoxide glutathione peroxidase; MTRR = MS reductase; NRIP1 = nuclear receptor interacting protein 1; POLG = mitochondrial 
DNA γ-polymerase; PRM = protamine; TNP = transition nuclear protein; PROK2 = prokineticin-2; PROKR2 = G-protein-coupled prokineticin receptor-2; SDHA = 
succinate dehydrogenase, subunit A; SYCP3 = synaptonemal complex protein 3; USP26 = ubiquitin-specific peptidase 26; USP9Y = ubiquitin-specific protease 9.
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infertile men. The few mutations with a cause–effect relationship 
with abnormal spermatogenesis are already of clinical use in 
selected groups of patients (congenital hypogonadotrophic 
hypogonadism, androgen resistance), whereas the clinical 
significance of polymorphisms (risk factors for abnormal 
spermatogenesis) and some of the causative mutations are still 
under debate. A few genes among the most promising ones have 
been selected for further discussion.
Based on data from model organisms and expression studies, 
genes expressing the highly conserved family of proteins 
DAZ, DAZL and BOULE have been proposed as major 
spermatogenesis candidate genes in humans. The DAZL gene is 
an autosomal homologue of the Y-chromosomal DAZ (deleted 
in azoospermia) gene cluster and maps to chromosome 3p24 
(Yen et al., 1996). All three family members encode RNA-
binding proteins with important roles in spermatogenesis (Yen, 
2004). Recently, new insights into the role of DAZL in synapsis 
formation in meiosis have been obtained (Reynolds et al., 
2007) based on the observation that Sycp3 is a target of DAZL-
mediated translation. Despite extensive mutation screening in the 
DAZL gene, to date only one homozygous mutation in exon 2, in 
a position close to the RNA-binding domain of the protein, has 
been found in an azoospermic man (Tung et al., 2006b). On the 
other hand, a high number of SNP have been identified (n = 85) 
and are mainly located in introns or in the 5 and 3 untranslated 
regions. The only exonic SNP reported as a susceptibility factor 
to oligo/azoospermia in the Chinese population is located in 
exon 3 (T54A) (Teng et al., 2002). Surprisingly, this variant was 
not even found in Caucasians (Bartoloni et al., 2004; Becherini 
et al., 2004; Tschanter et al., 2004). Specific haplotypes, based 
on the combination of SNP in noncoding regions, have been 
reported to be associated with sperm count (Tung et al., 2006a) 
or with spermatogenic failure (Teng et al., 2006). However, 
given the discrepancy between these two studies, it remains to 
be established if such an association does exist and if it is also 
present in Caucasians. No clinically relevant mutations for 
the BOULE (BOLL) gene have been reported (Lepretre et al., 
2004; Westerveld et al., 2005a). Recently, another evolutionary 
conserved protein, pumilio (PUM2), has been screened for 
mutations in patients with reduced sperm count (Kusz et al., 
2007). Despite a clear role of pumilio proteins in germ cell 
development and the specific expression pattern of PUM2 in 
the testis and ovary, the screening did not reveal any causative 
mutations.
The SYCP3 gene, located on chromosome 12, encodes a DNA-
binding protein as a component of the synaptonemal complex 
that regulates the synapsis between homologous chromosomes 
during meiosis of germ cells (Yuan et al., 2000). According to 
the predicted phenotype based on the function of this protein, a 
null mutation of Sycp3 in mice causes azoospermia with meiotic 
arrest. A mutation analysis in highly selected patients affected 
by maturation arrest identified a 1-bp deletion (643delA) that 
results in a premature stop codon and truncation of the C-
terminal, coiled-coil-forming region of the SYCP3 protein. The 
same mutation was found in two of 19 patients (Miyamoto et 
al., 2003). Unfortunately, no causative mutations were observed 
in subsequent European studies in a total of 70 selected patients 
(Martinez et al., 2007) with a similar testicular phenotype to 
that reported in previously by Stouffs et al. (2005a). These later 
findings exclude a relevant role for SYCP3 mutations in the 
aetiopathogenesis of spermatogenic arrest.
Another newly discovered component of the synaptonemal 
complex, the FKBP6 gene (located in chromosomal region 
7q11.23), was screened in 51 men with non-obstructive 
azoospermia through direct sequencing methods (Westerveld 
et al., 2005b). Only two heterozygous mutations (T173T 
and R183C) were identified that are likely to disrupt FKBP6 
protein function. However, both mutations were also found in 
normospermic controls, indicating that one FKBP6 allele appears 
to be sufficient for normal spermatogenesis. In conclusion, 
despite careful selection of patients with relatively homogeneous 
phenotype similar to that expected based on of mouse model, 
genetic defects of these two genes are an uncommon cause of 
azoospermia in humans.
Genes involved in compaction of the sperm nucleus are relevant 
for correct spermiogenesis. This remarkable repackaging event is 
related to the requirement for a unique chromatin architecture that 
would enable a specific transcription schedule after fertilization. 
Premature translation of PRM1 mRNA causes precocious nuclear 
condensation and arrests spermatid differentiation in mice (Lee 
et al., 1995), and the disruption of either the Prm1 or the Prm2 
gene in mice leads to haploinsufficiency, abnormal chromatin 
compaction, sperm DNA damage, and male infertility. Although 
reduction of protamine-2 has been reported in infertile men, 
mutations in the PRM2 gene have not been reported in association 
with reduced PRM2 content (Tanaka et al., 2003; Carrell et al., 
2007). Nishimune and coworkers (Tanaka et al., 2003) identified 
a number of SNP in both the PRM1 and the PRM2 genes in a 
large number of infertile men presenting mainly azoospermia, 
compared with proven fertile controls. No association between 
any of the SNP and infertility was observed. However, one 
mutation in the PRM2 gene induced a nonsense codon C248T 
and was present in heterozygosity in one azoospermic patient. 
Unfortunately, the testis histology of the patient is unknown 
and this makes it difficult to interpret the consequences of this 
mutation. In a recent study, a highly selected group of infertile 
patients was screened for PRM1 gene mutations (Iguchi et al., 
2005). A novel SNP, G197T, in a highly conserved region of the 
gene was identified in 3/30 patients. Based upon the absence of 
this SNP in over 700 individuals, and the recent confirmatory 
data from Ravel et al. (2007), it appears to be a promising new 
genetic risk factor for a specific subgroup of infertile patients with 
abnormal sperm DNA fragmentation and/or teratozoospermia.
Page and collaborators (Wang et al., 2001) reported an 
unexpectedly high number of X-linked genes expressed in the 
testis. This finding would suggest an important role for X-linked 
genes in male gametogenesis. However, up to now, only one 
X-linked gene (AR) has been investigated in large-scale studies 
(see the section on steroid receptor gene mutations), whereas 
two genes, USP26 and TAF7L, have been screened in relatively 
small study populations. The USP26 gene is located on the long 
arm of the X chromosome (Xq26.2) and belongs to the family 
of deubiquitinating enzymes that might be involved in histone 
removal and in the regulation of protein turnover in germ cells. It 
is specifically expressed in the testis throughout all stages and it 
was first proposed as having a key function in the early stages of 
spermatogenesis (Stouffs et al., 2005b). Sequence variants have 
been found mainly in azoospermic men (Paduch et al., 2005; 
Stouffs et al., 2005b) and a special cluster of three SNP have 
been proposed as potential genetic causes for spermatogenic 
failure. However, the finding of the same cluster in one man 
with normal spermatogenesis (Stouffs et al., 2006a) and its high 508
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frequency in men from sub-Saharan Africa and south and east 
Asia (Ravel et al., 2006) has questioned the pathogenic role 
of this specific haplotype. For the other X-linked gene TAF7L, 
which is homologous to the autosomal transcription factor gene 
TAF7 and is also expressed specifically in the testis, no causative 
mutations were found in a small study population (Stouffs et al., 
2006b). However, due to the low number of patients tested, the 
role of TAF7L mutations in spermatogenic failure remains to be 
established.
Another interesting group of candidate genes are retrogenes. 
Retrogenes originate from their progenitor genes by retroposition. 
Several retrogenes reported in recent studies are autosomal, 
originating from X-linked progenitor genes, and have evolved 
a testis-specific expression pattern. During male meiosis, sex 
chromosomes are segregated into a so-called ‘XY’ body and are 
silenced transcriptionally. The silencing of the X chromosome 
during male meiosis could therefore be the driving force behind 
the retroposition of X-linked genes to autosomes during evolution 
(Wang, 2004). Despite their potential interest, no large-scale 
analysis has been performed in testis-specific retrogenes so far.
The Y chromosome: gene mutations and 
polymorphisms
The long arm of the human Y chromosome hosts a number 
of genes involved in spermatogenesis, and several types of 
recurrent Yq deletions are firmly associated with spermatogenic 
failure (for review see McElreavey and Krausz, 1999; Krausz et 
al., 2003; Skaletsky et al., 2003). However, such observations 
do not allow attribution of spermatogenic function to any 
particular Y-chromosome-encoded protein because each of 
these deletions removes multiple genes. Despite the efforts of 
many research laboratories (results from around 2000 subjects 
screened for gene-specific deletions have been published) only 
four cases of confirmed isolated Yq gene mutation/deletion have 
been reported to date, and all are related to the AZFa region 
(Brown et al., 1998; Sun et al., 1999; Krausz et al., 2006). 
Since only one laboratory has performed mutation screening 
in AZF genes with direct sequencing (one mutation found out 
of 560 men), it is difficult to estimate the frequency of point 
mutations in AZF genes.
The rarity of single AZF gene deletions is in sharp contrast 
with the relatively high frequency of AZF deletions (classically 
divided into three azoospermia factor regions: AZFa, AZFb 
and AZFc; Vogt et al., 1996), which represent the most 
frequent molecular genetic cause of azoospermia and severe 
oligozoospermia (<5 × 106 spermatozoa/ml) (for a review see 
Krausz et al., 2003). A likely explanation is that the peculiar 
structure and the sequence organization of the Y chromosome 
make this chromosome prone to the loss of large regions such 
as the AZF gene regions. The complete removal of the AZFa 
and AZFb regions is associated with the severe testicular 
phenotype Sertoli cell-only syndrome, and spermatogenic arrest, 
respectively. The complete removal of the AZFc region causes 
a variable phenotype, which may range from azoospermia to 
oligozoospermia. The above-reported genotype/phenotype 
correlation confers to Y-deletion analysis a prognostic value for 
testicular sperm retrieval (Krausz and Degl’Innocenti, 2006). 
The deletion phenotypes suggest that the AZFa and AZFb 
regions contain at least one gene with essential spermatogenic 
function, whereas genes of the AZFc region are more likely to 
affect the efficiency of spermatogenesis.
The AZFa region contains two genes, namely DDX3Y (former 
DBY) and USP9Y, and the removal of both genes is associated 
with the complete absence of spermatogenic cells in the testis. 
USP9Y is the only Yq gene for which isolated mutations have 
been reported and no cases of confirmed isolated DBY deletions 
have been reported.
In three cases the exact breakpoint of the deletions has been 
defined (Sun et al., 1999; Krausz et al., 2006): the first, a 4-bp 
splice-donor site deletion resulting in severely truncated protein 
(Sun et al., 1999); the second, the removal of the last 13 exons; 
and the third, the loss of the promoter and the first 28 exons 
(Krausz et al., 2006). The first patient described by Sun et al. 
(1999) presented azoospermia with a testis histology showing 
hypospermatogenesis with occasional tubules containing only 
premeiotic or meiotic germ cells (spermatogenic arrest). This 
finding led to the conclusion that although complete absence 
or significant truncation of USP9Y protein is not enough to 
produce the full AZFa phenotype, it still causes azoospermia. In 
two unique cases of deletions removing part of the USP9Y gene, 
the phenotype was moderate oligoasthenoteratozoospermia and 
in both cases the mutations were spontaneously transmitted 
(Krausz et al., 2006). In one family the transmission occurred 
through two generations and represents the first description of 
a familial case of partial AZFa deletion. The second deletion 
was naturally transmitted from a subfertile father to his son, 
conceived while the couple were on a waiting list for assisted 
reproduction techniques. The phenotype of the two last 
cases clearly indicates that the protein is not required for the 
acquisition of sperm fertilizing ability, and, during human 
spermatogenesis, its role is more likely to be a ‘fine-tuner’, 
which improves efficiency rather than a provider of essential 
function. Moreover, it suggests that DDX3Y is the most likely 
candidate for the AZFa deletion phenotype.
Apart from the AZF genes, the TSPY (testis-specific protein, Y-
linked) gene may also be involved in spermatogenesis. On the 
basis of the expression pattern of TSPY, the homology of TSPY 
with SET (oncoprotein) and the interaction between TSPY 
and cyclin B Lau (1999) suggests a possible role of TSPY in 
regulating spermatogonia to enter meiosis. Its role in male 
infertility remains to be established. It is possible that copy-
number variations may influence spermatogenic potential; 
however, preliminary data showing an association with TSPY 
dosage by Vodicka et al. (2007) needs to be replicated by 
validated methods and on a large group of patients/controls.
Polymorphisms in the AZFc region
Apart from the classical AZF deletions, new types of Yq 
rearrangements have recently attracted the attention of geneticists 
and andrologists (for review see Noordam and Repping, 2006). 
The peculiar structure of the AZFc region (Figure 1) allows 
a series of rearrangements including the formation of partial 
deletions, deletion/duplications and partial duplications. 
Among them the most relevant is termed the ‘gr/gr’ deletion 
(Repping et al. 2003) and removes half of the AZFc content 
including two copies of the major AZFc candidate gene called 
DAZ (Reijo et al., 1995). This type of deletion is a significant 509
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risk factor in some populations but apparently not in others (for 
review see Krausz and Giachini, 2007). Contradictory results 
are likely to derive from methodological differences together 
with inappropriate control selection (only in a minority of 
studies are the controls normospermic men, and controls and 
patients are not matched for ethnic background in highly mixed 
populations such as Paris, the south of France and Brazil). 
Moreover, the majority of studies use sequence-tagged sites 
plus/minus polymerase chain reaction analysis, which alone 
does not provide information about the type of missing gene 
copies and about deletion/duplication events. For this reason 
the ideal methodology should be a combined analysis based on 
a first-step sequence-tagged site plus/minus analysis followed 
by a confirmatory dosage analysis restricted to the samples with 
suspected deletions, as described by Giachini et al. (2005). In 
the authors’ extended series of patients/controls (almost 1000 
subjects), after having performed a detailed molecular analysis 
and compared the frequencies between normospermic and 
infertile men, the gr/gr deletion proved to be a significant risk 
factor for abnormal spermatogenesis (Giachini et al. 2005; and 
unpublished data). The gr/gr deletions have been mainly found 
in oligozoospermic men but in very few cases (2/460) they 
have also reported in normospermic subjects. Among a number 
of plausible explanations for the heterogeneous phenotype 
the following explanations are postulated: (i) The presence 
of polymorphisms or mutations in the autosomal homologue 
of the DAZ gene DAZL (Becherini et al., 2004). However, 
similar to the AZFc-deleted patients, no new mutations were 
found in the entire coding region of the DAZL gene except 
the polymorphic Thr12-Ala change (T12A), which, due to its 
relatively high frequency in the normospermic group, does not 
seem to have any modulating effect (Giachini et al., 2005); (ii) 
The type of missing gene copies (DAZ1/DAZ2 and CDY1A 
versus DAZ3/DAZ4 and CDY1B); and (iii) The Y background 
(Y haplogroups). Therefore, it is likely that only a combined 
analysis will provide a tool for distinguishing between ‘neutral’ 
and ‘pathogenic’ types of deletions.
Recently, Yen and collaborators proposed that not only a reduction 
but also an excess of AZFc gene dosage could be deleterious 
for spermatogenesis (Lin et al., 2007). The authors report that 
partial gr/gr duplication (with a consequent double dosage of 
genes situated inside the region) is a significant risk factor for 
reduced sperm count in the Chinese population. Further studies 
are needed to define whether gr/gr duplication is a risk factor for 
reduced sperm count in other populations.
In conclusion, due to the above-mentioned biases (study design, 
ethnic differences, methodology), it is impossible to perform a 
reliable meta-analysis of published data on gr/gr deletion. In the 
few studies with appropriate control selection and confirmation 
of deletions, gr/gr deletions are clearly a risk factor for 
spermatogenic disturbances (Repping et al., 2003; Giachini et al., 
2005). Although it is not understood why in certain individuals 510
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Figure 1. The upper part is a schematic representation of the Y chromosome. Genes of the three azoospermia factor (AZF) regions are 
listed. Deletions of these regions result in spermatogenic failure. Multi-copy genes are in italics, whereas non-italic letters indicate 
single-copy genes. Underlined genes are expressed exclusively in the testis, whereas non-underlined are expressed ubiquitously. 
Transcription unit families are indicated with an asterisk. AZFb deletions (two subtypes) overlap with the AZFc region. Yq = long 
arm of the Y chromosome; Yp = short arm of the Y chromosome; PAR = pseudoautosomal region; MSY = male-specific Y with an 
extension of 63 Mb. The lower part shows the AZFc region in detail. This region contains a number of repeated sequences with 
the same orientation (arrows with the same shading) which through intrachromosomal recombination may lead to deletions. The 
clinically relevant gr/gr deletion is shown.
the deletion does not affect spermatogenesis, it is likely that 
Y background (Y haplogroups) plays an important modulating 
role. In fact, certain Y haplogroups contain constitutive gr/gr 
deletions and are diffused in certain populations, indicating 
that other compensatory mechanisms may exist on certain 
Y backgrounds (Repping et al., 2006). Given that fathers bearing 
gr/gr deletion will obligatorily transmit not only the deletion but 
also their entire Y chromosome (with or without compensatory 
structures) to their male offspring, it is likely that their sons 
will have a similar spermatogenic disturbance in the future. 
Thus, gr/gr deletion screening should be introduced among 
genetic diagnostic tests, especially prior to assisted reproduction 
techniques.
Conclusions
Thanks to the large-scale availability of molecular genetic tools 
and to the identification of an increasing number of candidate 
genes, the field of genetics of male infertility is rapidly 
evolving. However, the advancement in basic research has not 
been followed by a substantial increase in genetic diagnostic 
tests. Twelve years on from the description of the three AZF 
regions (Vogt et al., 1996), the sole molecular genetic test that 
is routinely proposed in severe oligo/azoospermic men is the 
screening for Yq microdeletions. The screening for mutations 
in genes with predicted specific spermatogenic function has 
not allowed the identification of clinically relevant mutations. 
Whether this is due to the real rarity of gene mutations, or to 
the inappropriateness of the currently used approaches, remains 
to be established. Recently, Krawetz proposed a new strategy 
based on sperm transcript profiling that may identify abnormal 
molecular pathway(s) in specific pathological conditions, such as 
for example teratozooseprmia (Platts et al., 2007). Information 
obtained from microarray analysis will allow the selection of 
candidate genes to be screened for mutations in a specific subset 
of patients with well-defined pathological phenotypes.
Another promising approach, based on the reverse transcription 
of full length mRNA from spermatozoa, has been proposed 
by Matzuk and colleagues (Yatsenko et al., 2006) and should 
accelerate the search for clinically relevant mutations. Given 
the origin of mRNA (haploid germ-cell-expressed genes), the 
usefulness of both approaches is limited to the detection of 
genetic defects involved in the post-meiotic maturation of germ 
cells.
As far as polymorphisms are concerned, the currently used 
case–control studies are often sources of contradictory results. 
The lack of reproducibility can be due to different factors already 
pointed out in the text. A substantial advancement will likely 
be achieved by the use of new technologies (microarrays) and 
from multicentre studies (high numbers of well-selected controls 
and patients of different ethnic origin) able to increase both the 
efficiency of the screening and the reliability of the results.
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